Defibrillator capability and all-cause mortality in patients receiving cardiac resynchronization therapy for non-ischemic cardiomyopathy: a Korean nationwide cohort study

Abstract Funding Acknowledgements Type of funding sources: None. Background Concerns exist about the benefit cardiac resynchronization therapy with a defibrillator (CRT-D) compared to those without (CRT-P), especially in patients non-ischemic cardiomyopathy. We evaluated association between capability and all-cause mortality receiving (CRT) for Methods From nationally registered cardiomyopathy Korea National Health Insurance Service (KNHIS) database, after exclusion ischemic heart disease, 1,478 newly-implanted CRT-P (n=258) or CRT-D (n=1220) were identified from 2008 2020. The was assessed propensity score (PS) weighting correct differences groups. Results Compared CRT-D, included more subjects older than 75. After PS weighting, over mean follow-up period 52.9 months (interquartile interval: 23.5-75.8), associated lower rate (6.5 vs 9.2 per 100 person-years) CRT-P. weighted risk death within 1 year (hazard ratio [HR]: 0.70 [95% CI, 0.53–0.91]; p = 0.009) 5 years (HR: 0.71 0.61–0.83]; < 0.001). consistent regardless subgroups, such as age, sex, registration, comorbidities. Conclusions In Korean cardiomyopathy, CRT reduced 1-year 5-year mortality. This across all investigated subgroups.